New Phase 3 trial: A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation — Shanghai Jeyou Pharmaceutical Co., Ltd.
Why now
Thesis: New Phase 3 trial registration for KRAS G12C NSCLC combo
Catalyst to watch: Enrollment progress or interim data
Main risk: Sponsor not in allowed ticker set
Why it matters
New Phase 3 trial registration for a KRAS G12C NSCLC combination; sponsor is not in the allowed ticker set.
Details
Sponsor: Shanghai Jeyou Pharmaceutical Co., Ltd.; Status: Not Yet Recruiting; Conditions: NSCLC; Interventions: Sosimerasib in combination with IN10018, Tislelizumab + Carboplatin + Pemetrexed; Enrollment: 416 (estimated); First posted: 2026-09-22; NCT: NCT07833202
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-22 12:00 UTC